-
Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide
-Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with…
-
Ferring highlights progress on social and environmental goals in Corporate Social Responsibility (CSR) Review 2015-2016
-Ferring Pharmaceuticals releases its second Corporate Social Responsibility (CSR) review, highlighting progress on social and environmental goals…
-
Ferring appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer
-Ferring Pharmaceuticals announced today that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer…
-
Ferring and CDI sign agreement granting Ferring exclusive marketing rights to VSL#3® in Europe and Canada
-Ferring Pharmaceuticals and CD Investments (CDI) announced today that they have signed an agreement granting Ferring exclusive European marketing…
-
Waking up to go to the toilet is the number one cause of a poor night’s sleep, say experts on World Sleep Day
-On World Sleep Day sleep experts encourage people to understand the value of healthy and solid sleep…
-
Ferring collaborates with ICF on development of a potential new treatment for anal fissures with a focus on improving quality of care for IBD patients
-Ferring Pharmaceuticals and Brazil-based Instituto de Ciências Farmacêuticas (ICF) today announced a research…
-
Ferring acquires ex-U.S. assets and rights for Vitaros® (alprostadil cream), Apricus’ on-demand topical cream for erectile dysfunction
-Ferring Pharmaceuticals today announced an agreement with Apricus Biosciences, Inc. (Nasdaq:APRI), granting Ferring global…
-
Ferring Announces Recipients of Innovation Grants Program 2016-2017
-Ferring today announced the recipients of the 2016-2017 Ferring Innovation Grants program, an annual initiative of the Ferring Research Institute…
-
Ferring and Foresee Pharmaceuticals Enter into Exclusive Development and Option Agreement
-Ferring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. (6576.TWO), announced today that the companies have entered into an exclusive…
-
Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic
-Ferring Pharmaceuticals and Enteris BioPharma, Inc. announced today that the companies have entered…
PRESS RELEASE 2017
PRESS RELEASE 2017